<DOC>
	<DOCNO>NCT00385008</DOCNO>
	<brief_summary>An evaluation tablet disintegration absorption gastric transit sumatriptan naproxen sodium TREXIMA tablet eletriptan RELPAX 40mg tablet .</brief_summary>
	<brief_title>TREXIMA RELPAX Gastric Scintigraphy Inside Outside Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Eletriptan</mesh_term>
	<criteria>Consented male nonpregnant female use adequate contraception , 18 55 year age , least 16 migraine per month past 6 month . Subjects exclude confirm suspected ischemic heart disease , uncontrolled hypertension screening ; history epilepsy structural brain lesion lower convulsive threshold ; confirm suspect cardiovascular , cerebrovascular , peripheral vascular , congenital heart disease , ischemic bowel disease ; impair hepatic renal function ; basilar hemiplegic migraine . Other exclusion criterion include use monoamine oxidase inhibitor within 2 week screen ; ergot prophylactic past 3 month ; anticoagulant ; smoke 10 cigarettes/day , evidence alcohol substance abuse ; GI bleeding disorder , inflammatory bowel disease ; concurrent medical psychiatric condition investigator 's opinion could affect interpretation efficacy safety information otherwise contraindicate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Combination product , sumatriptan succinate , naproxen sodium , absorption , pharmacokinetics , disintegration , gastric transit , gastric scintigraphy</keyword>
</DOC>